Research output per year
Research output per year
Personal profile
Biography
|
I am Personal Chair of Translational Liver Research and Honorary Consultant Hepatologist at the University of Edinburgh, UK. I have >30 years of hepatology research experience that spans basic science to clinical trials, giving me a multifaceted view of chronic liver disease. I am currently based in the new £92.5 million Institute for Regeneration and Repair (IRR) - the largest institute for regeneration and repair globally, hosting >600 scientists to facilitate the translation of discovery to therapy - and lead the ‘Translational Medicine’ theme in the Centre for Inflammation Research. I have a successful track record in translating scientific advances from bench to bedside and collaborating with Industry, running commercial and academic-sponsored observational studies (e.g., imaging/ biomarkers, large patient cohorts), interventional trials (e.g., recombinant relaxin, autologous macrophage cell therapy), discovery science, and mechanistic studies (e.g., preclinical evaluation of drug candidates). |
My clinical activity includes general hepatology clinics and management of hepatocellular carcinoma patients. I hold numerous advisory board/ clinical trial endpoint adjudication roles and am a National Institute for Health and Care Excellence (NICE) Medical Technologies Evaluation Programme (MTEP) advisor and Adoption & Implementation advisor. As an enthusiastic clinical educator, I contribute to undergraduate and postgraduate teaching at the University of Edinburgh. Patient and Public Involvement and Engagement is a high priority theme and, working closely with the British Liver Trust, helps to shape my research portfolio.
Education/Academic qualification
Doctor of Philosophy (PhD), University of Southampton
Award Date: 1 Jan 2007
Bachelor of Medicine, University of Southampton
Award Date: 1 Jan 1997
Bachelor of Science, University of Southampton
Award Date: 1 Jan 1996
Keywords
- RM Therapeutics. Pharmacology
- Liver fibrosis
- Portal hypertension
- Cirrhosis
- Hepatorenal syndrome
Fingerprint
Dive into the research topics where Jonathan Fallowfield is active. These topic labels come from the works of this person. Together they form a unique fingerprint.
- 1 Similar Profiles
Collaborations and top research areas from the last five years
Recent external collaboration on country/territory level. Dive into details by clicking on the dots or
-
TGFβ activity stabilizes ACC1 to increase de novo lipogenesis in metabolic liver disease
Mayfield, B., Yagashita, Y., Kang, J., Zhu, C., Mira, S., Kendall, T. J., Sun, Q., Meincke, M. E., Raphael, D., Li, M., Chen, S., Cullen, H., Meadows, S. M., Berchowitz, L. E., Carrer, M., Fallowfield, J. A., Schwabe, R. F., Valenti, L. & Pajvani, U. B., Aug 2026, In: Molecular Metabolism. 110, 102389.Research output: Contribution to journal › Article › peer-review
Open AccessFile -
Autologous macrophage therapy increases transplant-free survival in cirrhosis: Long-term follow-up of a phase 2 clinical trial
Brennan, P. N., Kilpatrick, A. M., Glover, A., Campana, L., Turner, M. L., Elliott, A., Duncan, A., Lachlan, N. J., Dillon, J. F., Fallowfield, J. A. & Forbes, S. J., 2 Jul 2026, In: Cell Stem Cell. 33, 7, p. 1098-1109.e3Research output: Contribution to journal › Article › peer-review
Open AccessFile -
Breast Cancer Hormone Receptor Status Determination from H&E-stained Biopsy Images using Pixel-level Classifiers
Wu, S., Nearchou, I. P., Prost, S., Fallowfield, J. A., Ueno, H., Tsuda, H., Ironside, A., Harrison, D. J. & Kendall, T. J., 27 Jun 2026, In: Cancers. 18, 13, 2085.Research output: Contribution to journal › Article › peer-review
Open AccessFile -
Gallstones: a driver of cardiovascular disease? A triangulation study
Fairfield, C. J., Drake, T., Pius, R., Cambridge, W. A., Clark, D. W., Cullen, L. C., Fallowfield, J. A., Hayward, C., Henderson, N. C., Iakovliev, A., Joshi, P. K., Mills, N. L., Ramachandran, P., Semple, R. K., Shaw, C. A., Sudlow, C. L., Timmers, P., Wilson, J. F., Wigmore, S. J. & Spiliopoulou, A. & 1 others, , 15 Jun 2026, In: Frontline Gastroenterology.Research output: Contribution to journal › Article › peer-review
Open AccessFile -
LiRNA: An Interactive Atlas of Human Liver RNAseq Databases
Sola, G. A., Shrestha, N., Ubieto, R. B., Jin, B., Kendall, T. J., Fallowfield, J. A. & Goodman, R. P., 8 Jun 2026, (E-pub ahead of print) In: JHEP Reports.Research output: Contribution to journal › Article › peer-review
Open AccessFile
-
SteatoSITE
Kendall, T. (Principal Investigator) & Fallowfield, J. (Co-investigator)
8/04/24 → 31/12/26
Project: Research
-
GPR35: mechanisms of action and agonism as a potential therapeutic strategy for non-alcoholic fatty liver diseases
Fallowfield, J. (Principal Investigator)
2/03/24 → 1/03/27
Project: Research
-
Halt-RONIN: Discovering chronic inflammation biomarkers that define key stages in the Healthy-to-NASH (non-alcoholic steatohepatitis) transition to inform early prevention and treatment strategies
Bagnaninchi, P. (Co-investigator), Fallowfield, J. (Co-investigator) & Morton, N. (Co-investigator)
1/12/22 → 30/11/26
Project: Research
-
Halt-RONIN: Halt-RONIN: Discovering Chronic Inflammation Biomarkers That Define Key Stages In The Healthy-to-NASH (non-alcoholic Steatohepatitis) Transition To Inform Early Prevention And Treatment Strategies
Nelson, L. (Principal Investigator), Fallowfield, J. (Co-investigator), Bagnaninchi, P. (Co-investigator) & Morton, N. (Co-investigator)
1/12/22 → 30/11/26
Project: Research
-
Centre for Precision Medicine For The Liverapy
Forbes, S. (Principal Investigator), Dear, J. (Co-investigator), Dhaliwal, K. (Co-investigator), Fallowfield, J. (Co-investigator) & Forbes, S. (Co-investigator)
1/06/22 → 31/05/27
Project: Research
Press/Media
-
Resolution Therapeutics to present EMERALD study design at the British Association for the Study of the Liver (BASL) annual meeting 2025
7/10/25
1 Media contribution
Press/Media: Research
-
Resolution Therapeutics to present EMERALD study design at the British Association for the Study of the Liver (BASL) annual meeting 2025
7/10/25
1 Media contribution
Press/Media: Research
-
Resolution Therapeutics announces first patient dosed in Phase I/II EMERALD study of RTX001 for the treatment of end-stage liver disease
3/09/25
1 Media contribution
Press/Media: Research
-
Resolution Therapeutics announces first patient dosed in Phase I/II EMERALD study of RTX001 for the treatment of end-stage liver disease
3/09/25
1 Media contribution
Press/Media: Research
-
First patient dosed in Scotland with new liver disease treatment
2/09/25
1 Media contribution
Press/Media: Research